Peritoneal carcinomatosis from colorectal or appendiceal origin: Correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement

Bree, Eelco de; Koops, Willem; Kröger, R; Ruth, Serge van; Witkamp, Arjen J.; Zoetmulder, F.A.N.

doi:10.1002/jso.20049

Cited by 256 publications

(168 citation statements)

References 41 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…In the remaining patients, the abdominal cavity was usually screened for peritoneal carcinomatosis by various imaging modalities such as CT scanning, but these studies are all known for their moderate 60-79% sensitivity in diagnosing peritoneal carcinomatosis. [16][17][18][19] Indeed, patients older than 80 years exhibited a smaller risk of presenting with peritoneal carcinomatosis. However, this does not explain the significant higher risk of presenting with peritoneal carcinomatosis at a younger age, especially younger than 60 years, for which we do not have a straightforward explanation.…”

Section: Epidemiologymentioning

confidence: 99%

“…Liver metastases only 8 (7-9) 12 (11)(12)(13)(14) Lung metastases only 22 (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) 20 (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) Other distant metastases at a single location Other distant metastases at multiple locations 7 (6-8) 8 (7)(8)(9)(10) Abbreviation: CI, confidence interval.…”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study

Lemmens

Klaver

Verwaal

et al. 2010

Intl Journal of Cancer

297

208

View full text Add to dashboard Cite

The aim of our study was to provide population‐based data on incidence and prognosis of synchronous peritoneal carcinomatosis and to evaluate predictors for its development. Diagnosed in 1995–2008, 18,738 cases of primary colorectal cancer were included. Predictors of peritoneal carcinomatosis were analysed by multivariable logistic regression analysis. Median survival in months was calculated by site of metastasis. In the study period, 904 patients were diagnosed with synchronous peritoneal carcinomatosis (4.8% of total, constituting 24% of patients presenting with M1 disease). The risk of peritoneal carcinomatosis was increased in case of advanced T stage [T4 vs. T1,2: odds ratio (OR) 4.7, confidence limits 4.0–5.6), advanced N stage [N0 vs. N1,2: OR 0.2 (0.1–0.2)], poor differentiation grade [OR 2.1 (1.8–2.5)], younger age [<60 years vs. 70–79 years: OR 1.4 (1.1–1.7)], mucinous adenocarcinoma [OR 2.0 (1.6–2.4)] and right‐sided localisation of primary tumour [left vs. right: OR 0.6 (0.5–0.7)]. Median survival of patients with peritoneum as single site of metastasis remained dismal [1995–2001: 7 (6–9) months; 2002–2008: 8 (6–11) months], contrasting the improvement among patients with liver metastases [1995–2001: 8 (7–9) months; 2002–2008: 12 (11–14) months]. To conclude, synchronous peritoneal metastases from colorectal cancer are more frequent among younger patients and among patients with advanced T stage, mucinous adenocarcinoma, right‐sided tumours and tumours that are poorly differentiated. The prognosis of synchronous peritoneal carcinomatosis remains poor with a median survival of 8 months and even worse if concomitant metastases in other organs are present.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study

Lemmens

Klaver

Verwaal

et al. 2010

Intl Journal of Cancer

297

208

View full text Add to dashboard Cite

show abstract

“…Although ct was not, in the past, very accurate in depicting peritoneal tumour deposits 16 , modern contrast-enhanced multislice ct is regarded as the fundamental imaging modality, and magnetic resonance imaging, positionemission tomography, laparoscopy, and serum tumour markers can be taken into consideration but are not considered essential 17 . Computed tomography enteroclysis provides information about small-bowel and mesenterium involvement 18 .…”

Section: Patient Selectionmentioning

confidence: 99%

Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapy—Current Perspectives

2016

View full text Add to dashboard Cite

Peritoneal carcinomatosis (ptc) represents advanced malignant disease and has generally been associated with a grim prognosis. Peritoneal surface malignancy is often the major source of morbidity and mortality; it is of major concern in cancer management. Although ptc is categorized as metastatic disease, it represents a special disease pattern considered to be a locoregional disease limited to the abdominal cavity. The combination of cytoreductive surgery (crs) and intraoperative hyperthermic intraperitoneal chemotherapy (hipec) has successfully been used as locoregional treatment for selected patients with ptc from gastric, colorectal, and ovarian cancer; with mesothelioma; and with pseudomyxoma peritonei. In the prophylactic setting, hipec can also be used to prevent ptc in high-risk patients, and the first results of the "second-look" approach are promising. Patient selection-in which the risks of perioperative morbidity and mortality, which are analogous to those for any other major gastrointestinal surgery, are assessed-is of utmost importance. Those risks have to be weighed against the anticipated survival benefit, which depends mainly on tumour biology, extent of disease, and probability of achieving complete crs. The present review discusses the principles of crs and hipec, the most significant recent clinical data, and current perspectives concerning the application of this treatment modality in various malignancies. Ongoing trials and future directions are noted. It appears that the combination of crs and hipec is an indispensable tool in the oncologist's armamentarium.

show abstract

“…However, the sensitivity and specificity at the peritoneal surfaces of the small bowel and its mesentery are not sufficient (Raptopoulos & Gourtsigiannis, 2001;Gonzalez-Moreno et al, 2009;de Bree et al, 2004). Disease at the small bowel constitutes a sentinel, limiting criterion in the decision making process involved cytoreduction because sufficient length of small bowel must remain in place to allow for adequate oral nutrition in the future.…”

Section: Wwwintechopencom Ovarian Cancer -Clinical and Therapeutic mentioning

confidence: 99%

“…Once the extent of peritoneal malignancy at the small bowel is the limit of cytoreductive surgery, the evaluation of the small bowel is a crucial component in the preoperative imaging assessment. Experience tells us that even the most sophisticated CT technology usually underestimates actual small bowel involvement revealed at surgical exploration (Gonzalez-Moreno et al, 2009;de Bree et al, 2004). Implants of less than 1 cm in size are detected with sensitivity 25-50% when helical-CT is used (Gonzalez-Moreno et al, 2009;de Bree et al, 2004).…”

Section: Wwwintechopencom Ovarian Cancer -Clinical and Therapeutic mentioning

confidence: 99%

Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer

Tentes¹,

Courcoutsakis²,

Prasopoulos³

2012

Ovarian Cancer - Clinical and Therapeutic Perspectives

View full text Add to dashboard Cite

Peritoneal carcinomatosis from colorectal or appendiceal origin: Correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement

Cited by 256 publications

References 41 publications

Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study

Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study

Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapy—Current Perspectives

Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer

Contact Info

Product

Resources

About